Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)

NCT02055638 is registered in ClinicalTrials.gov with Azevan Pharmaceuticals as lead sponsor.

NCT NCT02055638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02055638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)
Lead sponsor
Azevan Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2014
Completion date
May 31, 2016
Enrollment
97 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

intermittent explosive disorder